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http://dx.doi.org/10.1016/j.jmii.2013Background/purpose: The isoniazid (INH) resistance of Mycobacterium tuberculosis is caused
by mutations in the katG and inhA genes encoding for catalase-peroxidase and inhA, respec-
tively. Sequences of the katG and inhA gene of 70 isolates were analyzed to identify the mu-
tations and to compare the mutations with their related susceptibilities.
Methods: Sequences of the katG and inhA genes and the resistance profiles were analyzed for
the 70 M. tuberculosis isolates, collected from nine hospitals in Taiwan during the period from
1999 to 2011.
Results: Fifteen alleles were identified in the katG gene and two alleles were identified in the
inhA gene. Among the 15 alleles identified in the katG gene, 14 alleles were found in isolates
resistant to isoniazid, while only three alleles were found in isolates susceptible to isoniazid.
The mutations of the katG gene and their frequencies of 41 INH-resistant isolates were Ar-
g463Leu (51%), Ser315Thr (29%), Ser315Asn (9.8%), and other loci (22%). The sensitivity and
specificity of the Ser315Thr mutation for the detection of INH-resistant isolates were 29%
and 100%, respectively. The frequency of inhA gene mutation was low (2.44%) in the 41 INH-
resistant isolates.
Conclusion: The diverse alleles of the katG gene associated with INH resistance are present in
the M. tuberculosis isolates in Taiwan. These data may be applied to develop new probes for
various alleles associated with INH resistance in order to increase the sensitivity for theInfectious Diseases, Taichung Veterans General Hospital, No. 1650, Section 4, Taiwan Boulevard,
(Z.-Y. Shi).
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250 S.-T. Tseng et al.detection of genetically diverse M. tuberculosis isolates in different geographic areas. The di-
versity of mutations can also provide information for investigating the evolutional lineages of
M. tuberculosis isolates.
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Mycobacterium tuberculosis (TB) infection has been an
emerging global health issue. According to the World Health
Organization (WHO) Global Tuberculosis Report 2012,1
there were an estimated 8.7 million incident cases of TB
in 2011. There were also 1.4 million deaths from TB
(990,000 deaths among HIV-negative individuals and
430,000 among HIV-positive patients). There were an esti-
mated 12 million prevalent cases of TB in 2011, equivalent
to 170 cases per 100,000 population. Globally, 3.7%
(2.1e5.2%) of new cases and 20% (13e26%) of previously
treated cases are estimated to have MDR-TB (defined as
resistance to at least isoniazid and rifampicin). In 2011,
there were an estimated 630,000 cases of MDR-TB among
the world’s 12 million prevalent cases of TB. According to
the Taiwan Tuberculosis Control Report 2012,2 the annual
incident cases of TB were 12,634 (54.5 cases per 100,000
population) in 2011, and the estimated rates of MDR-TB
among new cases and previously treated cases were 1.0%
and 6.7%, respectively. In a study conducted by a tertiary
medical center in northern Taiwan in 2010, the resistance
patterns of M. tuberculosis isolates from 326 patients were
12.0% for isoniazid, 2.8% for rifampicin, 1.5% for etham-
butol, and 7.1% for streptomycin.3
Isoniazid is a prodrug that is activated by the catalase-
peroxidase enzyme encoded by the katG gene. Activated
isoniazid disrupts the synthesis of essential mycolic acids by
inhibiting inhA, the NADH-dependent enoyl-ACP reductase
enzyme encoded by inhA gene.4 Mutations of the katG gene
and inhA gene lead to reduction or loss of the activity of
catalase-peroxidase and structural change of the target of
isoniazid, and both result in resistance to isoniazid.5,6
The GenoType MTBDRplus (Hain Lifescience GmbH,
Nehren, Germany) is a test that uses PCR and DNA strip
hybridization for the rapid detection of isoniazid and
rifampicin resistance. The probes are designed to recognize
mutations of the katG (S315T) and inhA (C15T A16G, T8C,
and T8A) genes. A previous report in 2009 compared the
performance of GenoType MTBDRplus test and DNA
sequencing of the aforementioned loci in Taiwan.7 The
GenoType MTBDRplus test was less sensitive than DNA
sequencing (81.8% vs. 93.4%) for the detection of isoniazid
resistance because only limited codons were analyzed. The
authors suggest that new alleles of INH-resistant genes are
required to improve the sensitivity of GenoType MTBDRplus
test.7 Thus far, there has been no reports on the detailed
single nucleotide mutations of the katG and inhA genes
associated with resistance to isoniazid for M. tuberculosis
isolates in Taiwan. Hence, we conducted this study to
identify the detailed mutated sequences of the katG and
inhA genes of 70 M. tuberculosis isolates collected inTaiwan during the period from 1999 to 2011. Sequences of
their katG and inhA genes and resistance profiles of these
isolates were analyzed and compared with the mutations
of isoniazid-resistant strains from different geographic
regions.
Materials and methods
Collection of M. tuberculosis isolates
Seventy M. tuberculosis isolates were collected for this
study during the period from 1999 to 2011. Forty-six isolates
were resistant to at least one of the four drugs, including
isoniazid (INH), rifampicin (RMP), ethambutol (EMB), and
streptomycin (SM). Forty-one of the 46 isolates were
resistant to isoniazid. Among these 46 resistant isolates, 34
isolates were collected from Taichung Veterans General
Hospital (TCVGH) and 12 isolates were collected from the
other eight hospitals in northern Taiwan. Twenty-four iso-
lates were susceptible to all the four drugs. Among these 24
susceptible isolates, 12 isolates were collected from
TCVGH, and 12 isolates were collected from the other eight
hospitals in northern Taiwan. The sources of specimens
included sputum (62 isolates, 88.6%), cerebrospinal fluid (5,
7.1%), pleural effusion (2, 2.9%), and abscess (1, 1.4%).
Susceptibility test
The antimycobacterial susceptibility tests were performed
according to the CLSI M24-A2 modified agar proportion
method.8 The procedure is performed by inoculating equal
quantities of 100 and 10,000 dilutions of a standardized
inoculum (0.5w1 McFarland) onto 7H10 agar medium (Bio
Star, Taichung, Taiwan) with and without the test drug
and then incubating them at 35C, 10% CO2 for 21 days.
The number of colony-forming units growing on the drug-
containing medium compared with the number of those
growing on the drug-free medium is then determined and
expressed as a percentage. Resistance is defined as growth
on drug-containing agar greater than 1% of the number of
colonies that grow on the drug-free agar. The concentra-
tions of antituberculosis drugs were as follows: isoniazid,
0.2 mg/mL; streptomycin, 2.0 mg/mL; rifampicin, 1.0 mg/
mL; and ethambutol, 5.0 mg/mL. Multidrug resistance was
defined as isolates resistant to at least isoniazid and
rifampicin.8
DNA sequencing
The DNA was extracted by 10 mg/mL of proteinase K and 5%
Tween 20 in 200-mM Tris-HCl solution (pH Z 8.3) at 60C
Table 1 Primers, annealing temperature, and sequence length of sequencing
Gene (Accession no.
of reference strain)
Nucleotide position of primer Sequence Annealing
temp (C)
Sequence
length (bp)
katG (X68081) 202 (forward) GTCGCGACCATCGACGTTGA 65 1710
780 (reverse) GACGTCGTTCATGGCCATGC
673 (forward) ATGGGGCTGATCTACGTGA 65
1010 (reverse) TACAGGATCTCGAGGAAACT
892 (forward) TTGGGCTGGAAGAGCTCGTA 65
1460 (reverse) TCGCTACCACGGAACGACGA
1398 (forward) ATTGACTGTCTCACAGCTAG 65
2002 (reverse) AGGTGATACCCATGTCGAG
InhA (AF106077) Upstream of inhA (forward) TGGTCAGCTTCCTGGCTTCC 55 810
489 (reverse) GACCGTCATCCAGTTGTAG
272 (forward) TGGTGCATTCGATTGGGTTC 55
Downstream of inhA (reverse) GGTAACGTTCTCCAGGAAC
katG and inhA genes of TB in Taiwan 251overnight. The polymerase chain reaction (PCR) was per-
formed in a GeneAmp PCR System 9600 (Perkin-Elmer,
Norwalk, CT, USA) using the primer pairs listed in Table 1.
The PCR began with an initial 4-minute denaturation at
94C, followed by 35 cycles of denaturation at 95C for 1Table 2 Mutations of the katG gene and resistance profiles of
Alleles Codon, amino acid, and
nucleic acid change
No. of is
Allele 1a No mutation 23
Allele 2 506 GAG (Glu)/ TAG (stop) 1
Allele 3 202 GCC (Ala)/ GCA (Ala);
463 CGG (Arg)/ CTG (Leu)
1
Allele 4 463 CGG (Arg)/ CTG (Leu) 23
Allele 5 315 AGC (Ser)/ AAC (Asn);
463 CGG (Arg)/ CTG (Leu)
3
Allele 6 315 AGC (Ser)/ ACC (Thr) 6
Allele 7 127 CAG (Gln)/ CCG (Pro) 1
Allele 8 315 AGC (Ser)/ ACC (Thr);
463 CGG (Arg)/ CTG (Leu)
5
Allele 9 315 AGC (Ser)/ AAC (Asn) 1
Allele 10 463 CGG (Arg)/ CTG (Leu);
518 GGTC insertion
1
Allele 11 203 ACC (Thr)/ ACT (Thr);
463 CGG (Arg)/ CTG (Leu)
1
Allele 12 202 GCC (Ala)/ GCA (Ala);
315 AGC (Ser)/ ACC (Thr);
463 CGG (Arg)/ CTG (Leu)
1
Allele 13 352 CAA (Gln)/ GAA (Glu) 1
Allele 14 98 TAC (Tyr)/ TGC (Cys);
379 GCC (Ala)/ ACC (Thr);
463 CGG (Arg)/ CTG (Leu)
1
Allele 15 269 GGT (Gly)/ CGT (Arg) 1
a Allele 1 is identical to the reference sequence X68081.
EMB Z ethambutol; INH Z isoniazid; RMP Z rifampicin; SM Z streptminute, annealing at 55C for 2 minutes, extension at 72C
for 2 minutes, and a final extension step at 72C for 5 mi-
nutes. The sequence reactions were performed by adding
fluorescent terminators (Perkin-Elmer Applied Biosystems,
Foster City, CA, USA) and the primers used in the initial70 M. tuberculosis isolates
olates Resistance profiles (n)
INH (5); RMP (2); EMB (2); INH þ SM (1);
INH þ EMB (2); INH þ SM þ EMB (1);
Susceptible to all four drugs (10)
INH þ RMP (1)
Susceptible to all four drugs (1)
INH (1); INH þ RMP (2); RMP þ SM (1);
INH þ RMP þ SM (1); INH þ SM þ EMB (4);
Resistant to all four drugs (1);
Susceptible to all four drugs (13)
INH þ RMP þ SM (2); Resistant to all
four drugs (1)
INH (1); INHþEMB (1); INHþRMPþSM (3);
Resistant to all 4 drugs (1)
INHþRMPþSM (1)
INH (1); INH þ RMP (1); INH þ RMP þ SM (2);
INH þ SM þ EMB (1)
INH þ RMP (1)
INH þ RMP (1)
INH (1)
INH þ RMP (1)
INH þ SM (1)
Resistant to all four drugs (1)
INH (1)
omycin.
Table 3 Mutations of the inhA gene and resistance profiles of 70 M. tuberculosis isolates
Alleles Codon, amino acid, and
nucleic acid change
No. of
isolates
Resistance profiles (n)
Allele 1a No mutation 69 INH (10); RMP (2); EMB (2); INH þ EMB (3); INH þ RMP (7); INH þ SM (2);
RMP þ SM (1); INH þ RMP þ SM (9); INH þ SM þ EMB (6);
Resistant to all four drugs (3); Susceptible to all four drugs (24)
Allele 2 74 ATC (Ile)/ ACC (Thr) 1 Resistant to all four drugs
a Allele 1 is identical to the reference sequence, AF106077.
EMB Z ethambutol; INH Z isoniazid; RMP Z rifampicin; SM Z streptomycin.
252 S.-T. Tseng et al.PCR. The sequences were determined with an ABI PRISM
310 and 3100 automated DNA sequencer (Perkin-Elmer
Applied Biosystems, Foster City, CA). The sequences ob-
tained from all 70 isolates were compared. Each unique
mutated DNA fragment was defined as an allele.
Results
The mutations of the katG and inhA genes and their resis-
tance profiles are listed in Table 2 and Table 3, respec-
tively. Fifteen alleles were indentified in the katG gene,
and two alleles were identified in the inhA gene. Allele 1
represented the original sequence without mutation for
both the katG and inhA genes. The other alleles demon-
strated mutated sequences. Some of the alleles are listed
in GenBank under accession numbers AY155347 to
AY155354, AY178906, and AY155363.
Twenty-three isolates were assigned as allele 1 in the
katG gene, including 14 isolates susceptible to isoniazid, and
nine isolates resistant to isoniazid. Among the 15 alleles
identified in the katG gene, 14 alleles were found in isolates
resistant to isoniazid (alleles 1, 2, and 4e15), while only
three alleles were found in isolates susceptible to isoniazid
(alleles 1, 3, 4). The findings indicated that genetic poly-
morphisms in the katG gene could be associated with
isoniazid resistance. The common mutations, Arg463Leu,
Ser315Thr, and Ser315Asn, were identified in 8, 3, and 2
alleles, respectively. The mutations of the katG gene and
their frequencies of the 41 INH-resistant isolates wereTable 4 Sensitivity, specificity, PPV, and NPV of the katG gene
Mutated codon No. of isolates Sensitivity (
Ser315Thr 12 29
Ser315Asn 4 9.8
Arg463Leu 36 51
Ala202Alaa 2 2.4
Thr203Thra 1 2.4
Tyr98Cys 1 2.4
Gln127Pro 1 2.4
Gly269Arg 1 2.4
Gln352Glu 1 2.4
Ala379Thr 1 2.4
Glu506stop 1 2.4
518 GGTC insertion 1 2.4
a Ala202Ala was the silent mutation GCC202GCA. Thr203Thr was th
NPV Z negative predictive value; PPV Z positive predictive value.Arg463Leu (51%), Ser315Thr (29%), Ser315Asn (9.8%), and
other loci (22%). For the inhA gene, 69 isolates were assigned
as allele 1, including 29 isolates susceptible to isoniazid and
40 isolates resistant to isoniazid. Only one isolate was
assigned as allele 2 (Ile25Thr mutation), and it was resistant
to all the four drugs.
The statistical data, including sensitivity, specificity,
positive predictive value (PPV), and negative predictive
value (NPV), of the katG gene mutations for detection of
INH-resistance are listed in Table 4. The sensitivity, speci-
ficity, PPV, and NPV of mutated codon 315 (Ser315Thr and
Ser315Asn) were 39%, 100%, 100%, and 54%. Although the
sensitivity for each of the other seven mutated codons
(Tyr98Cys, Gln127Pro, Gly269Arg, Gln352Glu, Ala379Thr,
Glu506stop, and insertion in the codon 518) was low (2.4%),
the specificity and PPV for the detection of INH-resistance
were 100%. Identify these eight mutated codons (315, 98,
127, 269, 352, 379, 506, and 518) in M. tuberculosis isolates
may be helpful for the detection of INH-resistance because
of the high specificity and PPV.
Discussion
This study demonstrated the relationship between the
resistance profiles and the mutations of the katG and inhA
genes of M. tuberculosis isolates in Taiwan over a 12-year
period. There were significant genetic polymorphisms in
the katG gene, especially in isolates that were resistant
to isoniazid. The most common mutations among themutations to predict the resistance to isoniazid
%)a Specificity (%) PPV (%) NPV (%)
100 100 50
100 100 44
48 58 41
97 50 41
100 100 42
100 100 42
100 100 42
100 100 42
100 100 42
100 100 42
100 100 42
100 100 42
e silent mutation ACC203ACT.
Table 5 Frequency of the katG gene mutations in isoniazid-resistant M. tuberculosis isolates from different geographic
regions
Geographic area Country No. of isolates
resistant to INH
Frequencies of mutations among isolates resistant to INH (%)
S315T KatG mutations other than S315T No mutation
Southeastern Asia This study (Taiwan) 41 29.3 48.8 21.9
Taiwan7 242 50.4 43 6.6a
Shanghai, China11 242 62.8 26.5 10.7a
Bangladesh12 218 83.9 10.6 5.5a
Myanmar13 96 57.3 8.3 34.4
Mumbai, India14 104 21.15 NP NP
Northeastern Asia Korea15 52 23.1 53.8 23.1a
Central Asia Pakistan16 50 74 10 16
Northern Asia Russia17 24 91.7 8.3 0
Africa Sierra Leone18 32 71.9 15.6 12.5
Europe Swizerland19 101 65.6 28.6 5.8a
South America Brazil20 16 25 25 50
North America New York, USA21 33 36.4 15.1 48.5a
a No mutation detected in inhA regulatory region and katG gene.
INH Z isoniazid; NP Z not performed.
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Ser315Thr (29%), and Ser315Asn (9.8%). The Ser315Thr
(S315T) mutation has been the most widely studied muta-
tion of the katG gene worldwide and has been used in the
GenoType MTBDRplus as a molecular target to detect
isoniazid resistance. Enzymatic kinetic study demonstrated
that the Ser315Thr mutation triggered the least catalase
peroxidase activity among the 23 katG gene mutations
tested,9 which explained the high level of isoniazid resis-
tance of the S315T mutation.10 The frequency of Ser315Thr
mutation in INH-resistant isolates varies in different
geographic regions in the world, as shown in Table 5.7,11e21
In this study, the frequency of Ser315Thr mutation (29%)
was comparable to the results of previous studies from the
Mumbai (21.2%),14 Korea (23.1%),15 and Brazil (25%).20
However, a higher frequency of Ser315Thr mutation in the
katG gene was reported in other countries, such as
Shanghai, China (62.8%),11 Switzerland (65.6%),19 Africa
(71.9%),18 and Russia (91.7%).17 About 8.3% to 53% of mu-
tations are located in the katG gene but not the Ser315Thr
mutation.
The finding that the Ser315Thr mutation in the katG
gene occurs less frequently in this study in Taiwan has a
direct impact on the application of molecular techniques
for rapid detection of MDR-TB. The probes used in the
GenoType MTBDRplus are designed to recognize the muta-
tions of the katG (S315T) and inhA (C15T A16G, T8C, and
T8A) genes. By the GenoType MTBDRplus test, S315T mu-
tation in the katG gene were found in 122 (50.4%) of 242
INH-resistant isolates collected in Taiwan.7 Among the 41
INH-resistant isolates in this study, the katG mutations
associated with resistance were S315T (29%) and other loci
(48.8%). The sensitivity of GenoType MTBDRplus for
detection of the mutated katG gene appears to be low for
the isolates in this study. Therefore, it is reasonable to
develop new probes of the katG genes for detection of the
novel mutations which were selected under therapeutic
pressure or evolved in different geographic areas.
The sensitivity and specificity of Arg463Leu mutation for
the detection of INH resistance were only 51% and 48% inthis study. In a previous study, the proportions of isolates
from the Netherlands with Arg463Leu mutation were similar
in INH-susceptible isolates and INH-resistant or INH-
intermediate isolates (32% and 29%, respectively).22 Site-
directed mutagenesis experiments demonstrated that
Arg463Leu mutation did not alter the activity of the
catalase-peroxidase of M. tuberculosis.23 These data sug-
gested that the Arg463Leu mutation in the katG gene of M.
tuberculosis did not confer resistance to INH. All of the
isolates with the katG gene mutation were resistant to INH,
except allele 3 and some of the isolates of allele 4. Allele 3
possessed the mutations of GCC202GCA and Arg463Leu.
GCC202GCA is a silent mutation, and the Arg463Leu muta-
tion does not confer to isoniazid resistance. Allele 4 con-
tained Arg463Leu mutation alone. It was reasonable that
allele 3 and some of the isolates of allele 4 were susceptible
to INH.
Sreevatsan et al reported that the variants at katG
codon 463 and gyrA codon 95 were present at high fre-
quency.24 These two mutation sites are apparently not
related with antibiotic resistance and can be used as ge-
netic markers to trace the history of evolutional diver-
gence.24 In the present study, nine isolates with the
mutations of the katG gene located in codon 463 combined
with other loci (315 and 463; 463 and 518; 203 and 463; 202,
315, and 463; 98, 379, and 463) were multidrug resistant.
Further surveillance of the codon 463 and these mutation
loci in M. tuberculosis isolates will be helpful for tracing
the evolutional lineage of these resistant clones.
In contrast to the high frequencies of the katG gene
mutations, the frequency (1 of 41 INH-resistant isolates) of
the inhA gene mutation was low in this study. The only
isolate with the inhA gene mutation also possessed
Arg463Leu mutation in the katG gene. Among the 41 INH-
resistant isolates, 32 (78%) isolates had mutations in the
katG gene, and nine isolates (22%) had neither inhA nor
katG gene mutation. One of the possible mechanisms of the
drug resistance of M. tuberculosis isolates with normal
structural sequences of the inhA and katG gene may be
mutation in the inhA regulatory region,25 although it was
254 S.-T. Tseng et al.not demonstrated in this study. However, the frequency of
isoniazid resistance without mutations in the inhA regula-
tory region or the katG gene still ranged from 5.5w48.5%
worldwide, as shown in Table 5. According to the studies
performed by Ramaswamy et al10,26,27 and Zhang et al,28
approximately 10% to 25% of INH-resistant strains do not
contain mutations in any known gene targets for INH
resistance. Although mutations in at least 16 other genes
have been reported to be associated with INH resistance in
clinical isolates, their mechanisms of INH resistance remain
unclear.10,26,27 These results indicate that further in-
vestigations are needed in this issue.
Hazbo´n et al29 indicated that most studies examined
relatively small numbers of isolates or failed to include
sufficient numbers of drug susceptible controls to demon-
strate statistically significant associations between specific
mutations and INH resistance.6,17,23,26e35 The collection of
drug-resistant isolates is often limited by the relatively low
prevalence rate of drug-resistant M. tuberculosis isolates.
This bias is also present in the research of frequency of
rpoB gene mutations in M. tuberculosis isolates.36 The
limitation of this study is that small number of INH-resistant
isolates and an insufficient amount of INH-susceptible iso-
lates would result in bias in the proportion of resistant
isolates among the collection. Therefore, we focused on
the frequency of each point mutation in the resistant iso-
lates rather than the proportion in all of the isolates. The
drug-resistant isolates were collected from nine hospitals in
Taiwan during a 12-year period to avoid sampling from a
small region and in short period of time. The katG gene
mutations have demonstrated the variations that can pro-
vide basic information for further investigations. Another
limitation is that analysis of the regulatory region of the
inhA gene was not performed because of the limited
budget. Further investigation of the regulatory region of
the inhA gene is promising for the detailed analysis of
mutations related to INH-resistance.
In conclusion, the diverse alleles of the katG gene
associated with INH-resistance are present in the M.
tuberculosis isolates in Taiwan. These data may be applied
to develop new probes for various alleles associated with
INH-resistance, in order to increase the sensitivity for
detection of genetically diverse M. tuberculosis isolates in
different geographic areas. The diversity of mutations can
also provide information for investigating the evolutional
lineages of M. tuberculosis isolates.
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